Kyowa Kirin Stops KW-6356 Program Despite Promising Results
Kyowa Kirin has discontinued the clinical development of its investigational treatment, KW-6356, for Parkinson’s disease, despite Phase 2 clinical trial data showing promising results as a monotherapy or in combination with levodopa. The decision was based on the “global regulatory landscape, development hurdles, and timelines for potential market…